Studies have found that EGFR tyrosine kinase inhibitor (TKI)-resistant tumors transformed from non-small cell lung cancer (NSCLC) into SCLC and were sensitive to standard therapies for SCLC [37–39]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.